– USA, MA – Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system conditions, announced the appointment of Grant Bogle to its Board of Directors.
About Grant C. Bogle
Grant Bogle is a seasoned biotech executive with over three decades of operational experience in the biopharma industry and a strong focus on financial strategy, business development, corporate governance, and general management.
Grant Bogle was formerly CEO at Epizyme, Inc., a Boston-based biotechnology company that developed TAZVERIK, an FDA-approved oral EZH2 inhibitor for the treatment of relapsed/refractory follicular lymphoma. He assumed the CEO position in 2021 after having served on the Epizyme Board of Directors since 2019 and subsequently oversaw the 2022 acquisition of the company by Ipsen. Before that, Grant was SVP and CCO of TESARO, a publicly traded oncology company, which was acquired by GlaxoSmithKline in 2018 for $5.1 billion. Earlier, he served as SVP of pharmaceutical and biotech solutions at McKesson Specialty Health/U.S. Oncology and was a senior executive at Millennium Pharmaceuticals, Viacord, Roche, and Knoll Pharmaceutical Company.
Grant Bogle also serves on the board of the American School for the Deaf, the oldest permanent school for the deaf in the United States. He holds a B.A. in economics from Dartmouth College, an MBA from Columbia Business School, and served as a fellow in the 2020 cohort of the Advanced Leadership Initiative at Harvard University.
About Myrobalan Therapeutics
Myrobalan Therapeutics is a preclinical-stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, and innovative drug discovery tools, to create highly selective and brain-penetrant therapeutic candidates that are uniquely positioned for treating CNS conditions with significant unmet medical needs. Myrobalan’s pipeline of novel remyelination and anti-neuroinflammation programs is being advanced with the strategic support of renowned institutional co-founders. Myrobalan is committed to a transformed future in which patients with degenerative CNS conditions can access safe and effective medicines offering restorative potential.
For more information: https://myrotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.